Literature DB >> 33099471

Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis.

Hiroyuki Kato1, Keisuke Tateishi2, Hiroaki Fujiwara1,3, Hideaki Ijichi1, Keisuke Yamamoto1, Takuma Nakatsuka1, Miwako Kakiuchi1, Makoto Sano1,4, Yotaro Kudo1, Yoku Hayakawa1, Hayato Nakagawa1, Yasuo Tanaka1, Motoyuki Otsuka1, Yoshihiro Hirata5, Makoto Tachibana6, Yoichi Shinkai7, Kazuhiko Koike1.   

Abstract

BACKGROUND/AIM: The entire mechanisms by which epigenetic modifiers contribute to the development of pancreatic cancer remain unknown. Although the histone methyltransferase G9a is a promising target in human cancers, its role in pancreatic carcinogenesis has been under-studied. The aim of the study was to examine the role of G9a in pancreatic carcinogenesis by a gene-targeting mouse model.
MATERIALS AND METHODS: We established pancreas-specific G9aflox/flox mice and crossed them with Ptf1aCre/; KrasG12D/+ (KC) mice, which spontaneously develop pancreatic cancer. The phenotypes of the resulting KC mice with G9a deletion were examined. We analyzed transcriptomic data by microarray and genome-wide chromatin accessibility by transposase-accessible chromatin using sequencing. We established pancreatic organoids from KC mice.
RESULTS: G9a deficiency impaired the progression of pancreatic intraepithelial neoplasia (PanIN) and prolonged the survival of KC mice. The number of phosphorylated Erk-positive cells and Dclk1-positive cells, which are reported to be essential for the progression of PanIN, were decreased by G9a deletion. UNC0638, an inhibitor of G9a, suppressed the growth of organoids and increased global chromatin accessibility, especially around the regions including the protein phosphatase 2A genes.
CONCLUSION: Thus, our study suggested the functional interaction of G9a, Dclk1 and Mapk pathway in the Kras-driven pancreatic carcinogenesis. The inhibition of G9a may suppress the initiation of oncogenic Kras-driven pancreatic carcinogenesis. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Carcinogenesis; PDAC; PanIN; chromatin accessibility; epigenetics

Mesh:

Substances:

Year:  2020        PMID: 33099471      PMCID: PMC7675651          DOI: 10.21873/cgp.20224

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  47 in total

1.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia.

Authors:  Mitsuro Kanda; Hanno Matthaei; Jian Wu; Seung-Mo Hong; Jun Yu; Michael Borges; Ralph H Hruban; Anirban Maitra; Kenneth Kinzler; Bert Vogelstein; Michael Goggins
Journal:  Gastroenterology       Date:  2012-01-05       Impact factor: 22.682

Review 2.  H3K9 methyltransferase G9a and the related molecule GLP.

Authors:  Yoichi Shinkai; Makoto Tachibana
Journal:  Genes Dev       Date:  2011-04-15       Impact factor: 11.361

3.  A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns.

Authors:  Faiyaz Notta; Michelle Chan-Seng-Yue; Mathieu Lemire; Yilong Li; Gavin W Wilson; Ashton A Connor; Robert E Denroche; Sheng-Ben Liang; Andrew M K Brown; Jaeseung C Kim; Tao Wang; Jared T Simpson; Timothy Beck; Ayelet Borgida; Nicholas Buchner; Dianne Chadwick; Sara Hafezi-Bakhtiari; John E Dick; Lawrence Heisler; Michael A Hollingsworth; Emin Ibrahimov; Gun Ho Jang; Jeremy Johns; Lars G T Jorgensen; Calvin Law; Olga Ludkovski; Ilinca Lungu; Karen Ng; Danielle Pasternack; Gloria M Petersen; Liran I Shlush; Lee Timms; Ming-Sound Tsao; Julie M Wilson; Christina K Yung; George Zogopoulos; John M S Bartlett; Ludmil B Alexandrov; Francisco X Real; Sean P Cleary; Michael H Roehrl; John D McPherson; Lincoln D Stein; Thomas J Hudson; Peter J Campbell; Steven Gallinger
Journal:  Nature       Date:  2016-10-12       Impact factor: 49.962

4.  Pancreatic DCLK1+ cells originate distinctly from PDX1+ progenitors and contribute to the initiation of intraductal papillary mucinous neoplasm in mice.

Authors:  Wanglong Qiu; Helen E Remotti; Sophia M Tang; Elizabeth Wang; Lily Dobberteen; Ayman Lee Youssof; Joo Hee Lee; Edwin C Cheung; Gloria H Su
Journal:  Cancer Lett       Date:  2018-03-08       Impact factor: 8.679

Review 5.  Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth.

Authors:  M C Mumby; G Walter
Journal:  Physiol Rev       Date:  1993-10       Impact factor: 37.312

6.  MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice.

Authors:  Meredith A Collins; Wei Yan; Judith S Sebolt-Leopold; Marina Pasca di Magliano
Journal:  Gastroenterology       Date:  2013-12-06       Impact factor: 22.682

7.  G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response.

Authors:  Chi-Wen Luo; Jaw-Yuan Wang; Wen-Chun Hung; Guang Peng; Ya-Li Tsai; Tsung-Ming Chang; Chee-Yin Chai; Chih-Hung Lin; Mei-Ren Pan
Journal:  Radiother Oncol       Date:  2017-03-25       Impact factor: 6.280

8.  Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions.

Authors:  R H Hruban; N V Adsay; J Albores-Saavedra; C Compton; E S Garrett; S N Goodman; S E Kern; D S Klimstra; G Klöppel; D S Longnecker; J Lüttges; G J Offerhaus
Journal:  Am J Surg Pathol       Date:  2001-05       Impact factor: 6.394

9.  The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.

Authors:  Mei-Ren Pan; Ming-Chuan Hsu; Chi-Wen Luo; Li-Tzong Chen; Yan-Shen Shan; Wen-Chun Hung
Journal:  Oncotarget       Date:  2016-09-20

10.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

View more
  5 in total

1.  New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.

Authors:  Leticia Colyn; Gloria Alvarez-Sola; M Ujue Latasa; Carmen Berasain; Maite G Fernandez-Barrena; Matias A Avila; Iker Uriarte; Jose M Herranz; Maria Arechederra; George Vlachogiannis; Colin Rae; Antonio Pineda-Lucena; Andrea Casadei-Gardini; Federica Pedica; Luca Aldrighetti; Angeles López-López; Angeles López-Gonzálvez; Coral Barbas; Sergio Ciordia; Sebastiaan M Van Liempd; Juan M Falcón-Pérez; Jesus Urman; Bruno Sangro; Silve Vicent; Maria J Iraburu; Felipe Prosper; Leonard J Nelson; Jesus M Banales; Maria Luz Martinez-Chantar; Jose J G Marin; Chiara Braconi; Christian Trautwein; Fernando J Corrales; F Javier Cubero
Journal:  J Exp Clin Cancer Res       Date:  2022-05-26

Review 2.  Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment.

Authors:  Zhiyun Cao; Nathaniel Weygant; Parthasarathy Chandrakesan; Courtney W Houchen; Jun Peng; Dongfeng Qu
Journal:  Cancers (Basel)       Date:  2020-12-17       Impact factor: 6.639

Review 3.  Epigenetic Drugs and Their Immune Modulating Potential in Cancers.

Authors:  Yingying Liang; Sevin Turcan
Journal:  Biomedicines       Date:  2022-01-19

4.  TSPAN1-elevated FAM110A promotes pancreatic cancer progression by transcriptionally regulating HIST1H2BK.

Authors:  Hua Huang; Huan Li; Ting Zhao; Aamir Ali Khan; Ruining Pan; Sijia Wang; Shensen Wang; Xinhui Liu
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

5.  Inactivation of the Euchromatic Histone-Lysine N-Methyltransferase 2 Pathway in Pancreatic Epithelial Cells Antagonizes Cancer Initiation and Pancreatitis-Associated Promotion by Altering Growth and Immune Gene Expression Networks.

Authors:  Guillermo Urrutia; Thiago Milech de Assuncao; Angela J Mathison; Ann Salmonson; Romica Kerketta; Atefeh Zeighami; Timothy J Stodola; Volkan Adsay; Burcin Pehlivanoglu; Michael B Dwinell; Michael T Zimmermann; Juan L Iovanna; Raul Urrutia; Gwen Lomberk
Journal:  Front Cell Dev Biol       Date:  2021-06-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.